On Apr. 21, 2021, the NIH announced that a Phase 2/3 trial to evaluate a new fully-human polyclonal antibody therapeutic targeted to SARS-CoV-2, called SAB-185, had begun enrolling non-hospitalized people with mild or moderate cases of COVID-19.

The trial, ACTIV-2, was sponsored by the National Institute of Allergy and Infectious Diseases. The therapeutic was developed by SAB Biotherapeutics in Sioux Falls, South Dakota.